

# Trastuzumab for injection

(r-DNA origin)

For I.V. infusion, multiple-use vial  
(Lyophilised powder)



## Ogivri

(trastuzumab)

440 mg

1 vial of trastuzumab

 Mylan

**Composition:** Each vial contains: Trastuzumab (r-DNA origin) 440mg, L-Histidine 6.3mg, L-Histidine Hydrochloride 9.9 mg, Polyethylene Glycol 3350 (Macrogol 3350) 98.6mg, D-Sorbitol 337.9 mg.

**Storage:** Store at temperature between 2°C to 8°C. Reconstitute with 20 mL Bacteriostatic Water for Injection USP (diluent) provided in this pack. Do not freeze the reconstituted solution. Use the solution within 28 days after reconstitution.

**Keep out of reach of children.**

Do not use in case any foreign particulate matter is observed inside the vial after reconstitution.

Do not accept if seal is broken.

**Dosage and Administration:**

Read enclosed prescribing information sheet before use.

**Manufactured by:** M/s. Biocon Limited, Bengaluru, India

**Manufactured for:** Mylan Pharmaceuticals Private Limited, Plot No.1-A/2, MIDC industrial estate, Talaja, Panvel, Dist. Raigad – 410208, Maharashtra, India

Mfg Lic No.: KTK/28D/7/2006

BFXXXX/XX

**Imported by:** Meda Pharma (Thailand) Co.,Ltd., (A Mylan company), Bangkok, Thailand  
Reg No. 1C 15026/61 (NBS)

คำเตือนตามประกาศกระทรวงสาธารณสุข  
กรณีอาจทำให้เกิดอันตรายร้ายแรงได้  
ต้องใช้ภายใต้การควบคุมของแพทย์เท่านั้น



ยาควบคุมพิเศษ

ใช้เฉพาะโรงพยาบาล

Batch No:

Mfg Date:

Exp. Date:

ยาสิ้นอายุ